Table 3.

Multivariate cox analysis of associations between SLC7A5/SLC3A2 co-expression and clinicopathological parameters in the ER+/HER2− cohort.

mRNA Expression
	Recurrence-free survival
	HR (95% CI)	p	p *
SLC7A5−SLC3A2− vs. SLC7A5+SLC3A2+	2.0 (1.1–3.7)	0.01	0.05
Tumour size	1.2 (0.8–2.0)	0.2	0.3
Tumour grade	1.3 (0.9–1.9)	0.09	0.2
Nodal stage	1.1 (0.7–1.5)	0.6	0.7
	Distant metastasis-free survival
	HR (95% CI)	p	p *
SLC7A5−SLC3A2− vs. SLC7A5+SLC3A2+	2.1 (1.1–3.9)	0.01	0.05
Tumour size	1.8 (1.0–3.1)	0.02	0.05
Tumour grade	1.5 (1.0–2.2)	0.03	0.5
Nodal stage	1.3 (0.9–1.9)	0.1	0.12
	Breast-cancer-specific survival
	HR (95% CI)	p	p *
SLC7A5−SLC3A2− vs. SLC7A5+SLC3A2+	2.2 (1.1–4.3)	0.02	0.05
Tumour size	1.8 (1.0–3.2)	0.04	0.06
Tumour grade	2.0 (1.2–3.2)	0.002	0.01
Nodal stage	1.3 (0.8–2.0)	0.1	0.12
Protein expression
	Recurrence-free survival
	HR (95% CI)	p	p *
SLC7A5−SLC3A2− vs. SLC7A5+SLC3A2+	1.5 (1.0–2.4)	0.2	0.25
Tumour size	1.5 (1.1–2.0)	0.006	0.01
Tumour grade	1.4 (1.1–1.8)	0.001	0.002
Nodal stage	1.6 (1.3–1.9)	0.000008	<0.0001
	Distant metastasis-free survival
	HR (95% CI)	p	p *
SLC7A5−SLC3A2− vs. SLC7A5+SLC3A2+	1.5 (1.0–2.3)	0.03	0.037
Tumour size	1.6 (1.1–2.3)	0.004	0.006
Tumour grade	1.7 (1.3–2.3)	0.00001	<0.0001
Nodal stage	1.8 (1.4–2.2)	3.5 × 10−7	<0.0001
	Breast-cancer-specific survival
	HR (95% CI)	p	p *
SLC7A5−SLC3A2− vs. SLC7A5+SLC3A2+	1.7 (1.0–2.7)	0.02	0.03
Tumour size	1.3 (0.8–2.0)	0.16	0.2
Tumour grade	2.3 (1.7–3.3)	3.7 × 10−7	<0.0001
Nodal stage	1.8 (1.3–2.3)	0.00002	0.0001

p *: Adjusted p value.